Why Medicare price negotiations matter for Novo Nordisk, AstraZeneca, and other European pharma companies

Impact · against what's priced in

The market has largely anticipated the IRA's mandatory price cuts, as evidenced by muted share reactions, but the ongoing implementation of 'Most Favored Nation' pricing creates a new, less predictable layer of revenue risk. Novo Nordisk faces the most significant immediate headwind with a 71% discount on Ozempic, though strategic US investments aim to mitigate broader tariff risks.

NVO−0.60

No priced-in read yet